Boston Scientific announced today that its TAXUS Element drug eluting stent has been granted the CE Mark, and will consequently be launched in Europe next month. The stent utilizes the same unique platinum chromium alloy and structure as the PROMUS Element stent which we reported on last October, and demonstrated superior performance to the company’s TAXUS Express2 stent in a clinical trial.
From the press release:
The TAXUS Element Stent is designed specifically for coronary stenting and leverages the performance advantages of the Element platform with a decade of clinical success from the TAXUS program. The novel stent architecture and proprietary platinum chromium alloy combine to offer greater radial strength and flexibility. The stent architecture helps create consistent lesion coverage and drug distribution while improving deliverability, which is enhanced by an advanced catheter delivery system. The higher density alloy provides superior visibility and reduced recoil while permitting thinner struts compared to prior-generation stents.